ABSTRACT
Note: This monograph refers specifically to the liposomal doxorubicin formulation marketed in the UK as Caelyx ® and in the USA as Doxil ® . Its content cannot be applied to conventional doxorubicin or to other liposomal preparations that may have very different pharmacokinetic and pharmacodynamic properties. Specifically, it cannot be applied to Myocet ® , another liposomal product.
